Drug Profile
Mitazalimab - Alligator Bioscience
Alternative Names: ADC 1013; JNJ 7107; JNJ-64457107; VanalimabLatest Information Update: 08 Feb 2024
Price :
$50
*
At a glance
- Originator Alligator Bioscience
- Developer Alligator Bioscience; Erasmus MC; Janssen Biotech; Scandion Oncology; University of Pennsylvania
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pancreatic cancer
- Preclinical Cancer
- No development reported Solid tumours
Most Recent Events
- 29 Jan 2024 Alligator Bioscience plans a phase III registration trial for Pancreatic Cancer in early 2025 (IV)
- 29 Jan 2024 Efficacy and adverse event data from a phase II OPTIMIZE-1 trial in Pancreatic cancer released by Alligator Bioscience
- 19 Jan 2024 University of California and National Cancer Institute plans a phase I trial for Pancreatic cancer (Late stage disease, Inoperable/Unresectable) in USA (Intratumoral, Injection), (NCT06205849)